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SUPPLEMENTARY MATERIAL 
Appendix 1 Table 1 Model input parameters from the TASMIN-SR model (reproduced from Penaloza-
Ramos et al (2015)) 
Parameter Input Sources 
CVD risk in patients with DM      
Stroke   
60-69 years old 0.0196 
NICE, Diabetes(37)  70-79 years old 0.0262 
80-89 years old 0.0298 
MI   
60-69 years old 0.0089 
NICE, Diabetes(37)  70-79 years old 0.0100 
80-89 years old 0.0111 
UA   
60-69 years old 0.0041 
NICE, Diabetes(37)  70-79 years old 0.0047 
80-89 years old 0.0052 
CVD risk in patients with CKD  
 Stroke   
60-69 years old 0.0072 
Kerr et al (2012)(38) 70-79 years old 0.0147 
80-89 years old 0.0189 
MI   
60-69 years old 0.0051 
Kerr et al (2012)(38) 70-79 years old 0.0113 
80-89 years old 0.0171 
UA   
60-69 years old 0.0024 
Kerr et al (2012)(38) 70-79 years old 0.0054 
80-89 years old 0.0081 
CVD risk in patients with stroke  
 Stroke   
60-69 years old 0.0348 PROGRESS (1999) & 
NICE, Lipid 
modification 
guidelines(41, 42) 
70-79 years old 0.0590 
80-89 years old 0.0715 
MI   
60-69 years old 0.0139 PROGRESS (1999) & 
NICE, Lipid 
modification 
guidelines(41, 42) 
70-79 years old 0.0232 
80-89 years old 0.0232 
UA   
60-69 years old 0.0139 PROGRESS (1999) & 
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Parameter Input Sources 
70-79 years old 0.0232 NICE, Lipid 
modification 
guidelines(41, 42) 80-89 years old 0.0232 
CVD risk in patients with CHD  
 Stroke   
60-69 years old 0.0348 NICE, Lipid 
modification and 
Hypertension 
guidelines(3, 41) 
70-79 years old 0.0590 
80-89 years old 0.0715 
MI   
60-69 years old 0.0666 NICE, Lipid 
modification and 
Hypertension 
guidelines(3, 41) 
70-79 years old 0.1112 
80-89 years old 0.1112 
UA   
60-69 years old 0.0528 NICE, Lipid 
modification and 
Hypertension 
guidelines(3, 41) 
70-79 years old 0.0882 
80-89 years old 0.0882 
Age-related relative risks   
MI, UA  – self-management    
60-69 years old 0.63 TASMIN-SR trial & 
Law at al (2009)(6, 
47)  
70-79 years old 0.69 
80-89 years old 0.75 
Stroke – self-management   
 60-69 years old 0.54 TASMIN-SR trial & 
Law at al (2009)(6, 
47)  
70-79 years old 0.59 
80-89 years old 0.75 
MI, UA - usual care   
 60-69 years old 0.82 TASMIN-SR trial & 
Law at al (2009)(6, 
47)  
70-79 years old 0.85 
80-89 years old 0.88 
Stroke - usual care   
 60-69 years old 0.76 TASMIN-SR trial & 
Law at al (2009)(6, 
47)  
70-79 years old 0.81 
80-89 years old 0.88 
Cost of death 0 By definition 
Annual discount rate for costs 0.035 Gray et al (2011)(53) 
Annual discount rate for utility 0.035 Gray et al (2011)(53) 
Death utility 0 By definition 
Average age of cohort at time of intervention 
(years) 70 TASMIN-SR trial(6) 
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Appendix 1 Table 2 Input parameters and their distributions from the TASMIN-SR model (reproduced 
from Penaloza-Ramos et al (2015) 
Description Input Distribution a b 
Probability of death from Stroke  0.23 Beta 125 420 
Probability of death from MI 0.23 Beta 155 520 
   alpha lambda 
Cost of well state self-
monitoring 74 Gamma 1 0.0136 
Cost of well state for Usual care 
arm 62 Gamma 1 0.0161 
Cost acute angina 3292 Gamma 1 0.0003 
Cost acute MI 5487 Gamma 1 0.0002 
Cost acute Stroke 11020 Gamma 1 0.0001 
Cost chronic angina 286 Gamma 1 0.0035 
Cost chronic MI 286 Gamma 1 0.0035 
Cost chronic Stroke 1361 Gamma 1 0.0007 
Cost of intervention 35 Gamma 1 0.0286 
   mean s.d. 
Multiplier used to adjust for 
initial health states by age 1 Normal 1 0.0125 
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Appendix 1 Table 3 Data extraction instrument for the assessment of structural uncertainty for the papers included in the review  
Author, year 
 
Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
Kaambwa et 
al. 38 
  
Yes Yes Yes 
Authors argued that self-monitoring of 
hypertension (as a means to lower blood 
pressure) has been largely evaluated; previous CE 
results found to be inconsistent plus not been 
extrapolated to the longer term. Their study 
examined the long-term cost-effectiveness of 
self-monitoring combined with self-titration (i.e., 
self-management) of blood pressure 
Four acute health states (Stroke, MI, Angina, and HF) and 
death were considered. It was not mentioned how health 
states were identified; authors acknowledged to have 
made an assumption that CHD consisted of MI, HF and 
angina (this was reflected in the structure of their Markov 
model); the risk of secondary events, including 
progression of disease, was not modelled and was 
acknowledged as a weakness 
Adverse effects such as anxiety or 
drug side effects were not 
modelled due to lack of data, 
however, trial data found minimal 
differences; effectiveness of the 
intervention after the year of the 
trial was unknown however the 
effect of various potential 
reductions in efficacy was tested in 
SA. Lifetime time horizon was 
tested in SA 
Stevanovic et 
al. 71 
  
Yes Yes Yes 
Authors argued that health and economic 
consequences of newer anti-hypertensive agents 
such as ACEIs and ARBs were not available at the 
time of the study in Netherlands. As a result, 
authors compared HCT 25 mg (diuretics) versus 
HCT/ACEIs versus HCT/ARBs versus no treatment 
One acute health state (Acute CVD), a chronic health state 
(Stable CVD) and death were considered. The inclusion of 
states in the Markov model was not justified. Risk of 
secondary events was assumed to be equal to the risk of a 
first non-fatal CVD event. This assumption was  
acknowledged to lead to an under-estimation of the CVD 
risk and compensated with the adoption of an increased 
risk of death in patients experiencing non-fatal CVD 
events 
Adverse effect(s) from 
antihypertensive treatment was 
not considered; large uncertainty 
ranges around the expected values 
of the SCORE input parameters 
(model for ten year risk of fatal 
cardiovascular disease) used in the 
model for both 10-year and 
lifetime horizons, as tested through 
PSA and ANCOVA analyses 
Wu et al. 72 Yes No No 
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Author, year 
 
Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
  
Comparators resulted from the results of a meta-
analysis study indicating that Norvasc 
(Amlodipine) was superior to ARBs in the 
prevention of stroke and MI in hypertensive 
patients. 
Two acute (Stroke and MI) and its corresponding chronic 
health states were considered. No justification was given 
for the inclusion of states in their Markov model; authors 
did not discuss the possibility of recurrent events, 
however they acknowledged as a weakness in the model 
not including the risk of patients having both stroke and 
MI due to lack of data 
Even though an assumption was 
adopted that the risk of stroke or 
MI and the mortality risk during the 
lifetime of the model (5-years) will 
remain fixed, this assumption was 
not tested in SA  
Kourlaba et 
al. 73 
  
Yes No No 
Comparators resulted from answering the 
research question in light of recent guidelines in 
Greece for the use of combined therapy to treat 
hypertension 
Two acute (MI and Stroke) health states and its 
corresponding chronic health states were modelled. No 
movement from MI to stroke was assumed; it was 
acknowledged as a limitation; risk of secondary events in 
their Markov model was not considered; same risk of CVD 
death was assumed (independently of whether a patient 
has experienced a previous CVD). None of these 
assumptions was tested in SA 
No evidence or discussion 
presented on this respect 
Ekwunife et 
al. 74 
Yes Yes No 
Comparators were identified from hypertension 
guidelines in Nigeria 
Two acute health states (Stroke and CHD) were modelled 
and two chronic post event health states. The model 
reflected the pathway of patients with hypertension 
starting in an asymptomatic health state, and then 
moving to a cardiovascular state (CHD or stroke) and 
death. The authors did not consider secondary events and 
this was not discussed. The authors used a Markov model   
Wisloff  et al. Yes Yes No 
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Author, year 
 
Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
75 
  
Alternatives were aimed at contribute towards 
the discussion around intervention thresholds 
and the choice of first-line drug and 'add on' 
drugs 
Four acute health states (Stroke, AMI, Angina and HF) and 
two post event health states (Post-Stroke and Post-CVD) 
were considered. Health events in the Markov model 
reflected the asymptomatic stages, cardiovascular life and 
death of patients; the model allowed for secondary 
events after which the model assumed patients will move 
to the worst health state; some assumptions regarding 
risk of secondary events were based on expert opinion. 
These assumptions were not tested in SA 
The authors used observed 
incidence rates to reflect risk 
factors using registry data; this was 
acknowledged as a limitation 
however was not tested in SA 
Granstrom et 
al. 78 
  
Yes Yes No 
Justified on the grounds that no head to head 
randomised comparative studies were previously 
performed comparing Candesartan and Losartan; 
authors acknowledged as a limitation that there 
may be ARB comparators more relevant to 
Candesartan than Losartan in other health care 
setting 
The authors considered health states (HF, PAD and 
Arrhythmia), post event health states (post-MI and post 
Stroke) and a chronic health state (IHD). Health states in 
the Markov model, including post MI and post stroke 
were based on CVD events measured in a registry study 
(authors commented and acknowledged a potential risk 
of confounding); after a CVD event an increased risk of 
mortality was applied (no SA to test for these 
assumptions) 
  
Baker et al. 79 
Yes Yes Yes 
Comparators were justified in view of the 
concerns surrounding non-medical ARB switching 
after Simvastatin became a generic product 
leading to a number of patients being switched 
from branded atorvastatin to generic Simvastatin 
for economic rather than medical reasons 
Health states were designed to reflect the course and 
history of CVD events in a typical patient with 
hypertension (CVD event free, post CVD, and death). 
Although secondary CVD events were not explicitly 
considered in the model, patients in the post-event state 
were subject to an increased risk of death reflecting their 
disease state 
The model assumed that Valsartan 
remained on patent for the first 
2.75 years of the model time 
horizon and Losartan for only 4 
months after which generic 
formulations would become 
available. No side effects were 
modelled, which was 
acknowledged as a weakness 
Perman et al. Yes Yes Yes 
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Author, year 
 
Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
70 
  
Justified on the basis that previous evidence was 
favourable for hypertension programmes as 
compared to drug treatments 
The health states were: an acute MI event, no event and 
death. The inclusion/exclusion of health states in the 
Markov model was not discussed but rather just 
introduced; an interesting assumption in the model was 
that patients presenting an acute CVD event could have or 
not have hospital attention? Risk of secondary events was 
considered. This was not tested in SA 
The discount rate was considered 
as a structural variable and thus 
analyses were performed with 
different discount rates ranging 
from 0%-12% 
Ekman et al. 
76 
  
Yes No Yes 
The comparators corresponded to those found to 
have mild side effects as per previous clinical 
trials; it was acknowledged as a weakness not to 
include other comparators such as diuretics 
Four acute health states (Angina, MI, CHF and stroke), a 
post MI, and post stroke health state were modelled. No 
particular explanation was given for the 
inclusion/exclusion of health states. The Markov model 
assumed that patients may undergo revascularization 
procedures while in the MI or angina health states; 
recurrence of events was modelled however 
acknowledged that data was limited to reflect how risks 
of recurrent strokes or MIs vary depending on various 
disease histories. 
Treatment effects were supposed 
to last five years; SA tested the 
sensitivity of the model to changes 
in the duration of the 
antihypertensive treatment and 
variation of discount rate (between 
0% to 8%) and measure of LYG 
instead of QALYs 
Gandjour et 
al. 68 
  
Yes No No 
Comparators resulted from the research question 
which is whether the health service can reduce 
the underuse of hypertensive medication among 
the German population through a national 
programme 
Three acute health states (MI, stroke and renal failure) 
were modelled. No particular reason argued for the 
inclusion/exclusion of health states in the Markov model; 
treatment and its effect were assumed to last a lifetime; 
secondary events were not modelled but captured 
through the mortality rates of patients after a CVD event. 
Model assumptions were not tested in SA 
  
Montgomery 
et al. 69 
Yes No No 
Comparators resulted from the research question 
which is whether incorporating patients’ 
preferences into the decision-making process 
A single acute CVD health state was considered with 
variations to account for the impact of side effects and 
treatment or lack of it. No explanation was given for the  
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Author, year 
 
Inclusion/exclusion of potentially relevant 
comparators 
Health states included/excluded, recurrence of events; 
type of model 
Inclusion/exclusion of other 
assumptions affecting the 
structure of the model 
may have an important influence on treatment 
recommendations for individual patients 
inclusion/exclusion of health states in the Markov model; 
secondary events were not modelled and the assumption 
that any second cardiovascular event was fatal was 
adopted. Model assumptions were not tested in SA 
Nordmann et 
al. 77 
  
Yes No No 
Comparators were chosen in line with 
hypertension guidelines for first-line 
antihypertensive therapy from both, the Joint 
National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure 
(JNC-VI) and the World Health Organization 
(WHO) 
Three acute health states (CAD, CVD and CHF) were 
considered. Authors argued to have included the most 
common CVD outcomes as health states in the Markov 
model; the model allowed one opportunity to switch from 
conventional therapy to ACE inhibitors in response to 
adverse effects or lack of efficacy; recurrence of events 
was modelled 
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Appendix 1 Table 4 Results of cost-effectiveness after increasing /decreasing total costs by 
40% 
Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
TASMIN-SR           
Increasing costs  
    
  
Usual care 
  
13,805  
  
7.0946  
  
  
Self-management 
   
12,596  
   
7.4390  -1,209 0.3444 
 
Dominant  
Decreasing costs  
    
  
Usual care 
    
5,917  
  
7.0946  
  
  
Self-management 
     
5,398  
   
7.4390  -518 0.3444 
 
Dominant  
Model 1 
    
  
Increasing costs  
    
  
Usual care 
  
13,234  
  
6.9102  
  
  
Self-management 
   
12,339  
   
7.2311  -895 0.3210 
 
Dominant  
Decreasing costs  
    
  
Usual care 
    
5,671  
  
6.9102  
  
  
Self-management 
     
5,287  
   
7.2311  -384 0.3210 
 
Dominant  
Model 2 
          
Increasing costs  
    
  
Usual care 
  
13,797  
  
7.1612  
  
  
Self-management 
   
12,402  
   
7.5057  -1,394 0.3445 
 
Dominant  
Decreasing costs  
    
  
Usual care 
    
5,913  
  
7.1612  
  
  
Self-management 
     
5,315  
   
7.5057  -598 0.3445 
 
Dominant  
Model 3 
    
  
Increasing costs  
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Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
Usual care 
   
13,574  
   
5.9274  
  
  
Self-management 
   
12,819  
   
6.2721  -755 0.3446 
 
Dominant  
Decreasing costs  
    
  
Usual care 
    
7,069  
  
5.9274  
  
  
Self-management 
     
6,607  
   
6.2721  -462 0.3446 
 
Dominant  
Model 4 
    
  
Increasing costs  
    
  
Usual care 
      
16,097  
           
7.0489        
Self-management 
       
14,464  
            
7.4085  -1,633 0.3596 
 
Dominant  
Decreasing costs  
    
  
Usual care 
       
6,899  
           
7.0489        
Self-management 
        
6,199  
            
7.4085  -700 0.3596 
 
Dominant  
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Appendix 1 Table 5 Results of cost-effectiveness after increasing /decreasing total costs by 
200% and 50% respectively 
Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
TASMIN-SR 
          
Increasing costs 200% 
    
  
Usual care 
      
19,728  
           
7.0946        
Self-management 
       
17,899  
            
7.4390  -1,829 0.3444  Dominant  
Decreasing costs 50%  
    
  
Usual care 
       
4,931  
           
7.0946        
Self-management 
        
4,550  
            
7.4390  -382 0.3444  Dominant  
Model 1 
  
 
 
 
  
Increasing costs 200% 
    
  
Usual care 
      
18,905  
           
6.9102        
Self-management 
       
17,528  
            
7.2311  -1,376 0.3210  Dominant  
Decreasing costs 50%  
    
  
Usual care 
       
4,726  
           
6.9102        
Self-management 
        
4,455  
            
7.2311  -271 0.3210  Dominant  
Model 2 
          
Increasing costs 200% 
    
  
Usual care 
      
19,717  
           
7.1612        
Self-management 
       
17,626  
            
7.5057  -2,091 0.3445  Dominant  
Decreasing costs 50%  
    
  
Usual care 
       
4,928  
           
7.1612        
Self-management 
        
4,479  
            
7.5057  -449 0.3445  Dominant  
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Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
Model 3 
    
  
Increasing costs 200% 
    
  
Usual care 
      
19,396  
           
5.9274        
Self-management 
       
18,218  
            
6.2721  -1,179 0.3446  Dominant  
Decreasing costs 50%  
    
  
Usual care 
       
4,848  
           
5.9274        
Self-management 
        
4,628  
            
6.2721  -220 0.3446  Dominant  
Model 4 
    
  
Increasing costs 200% 
    
  
Usual care 
      
31,071  
         
7.0489        
Self-management 
       
27,771  
         
7.4085  -3,301 0.3596  Dominant  
Decreasing costs 50%  
    
  
Usual care 
      
7,766  
        
7.0489        
Self-management 
        
7,011  
            
7.4085  
-755 
0.3596 
 Dominant  
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Appendix 1 Table 6 Results of cost-effectiveness after altering the time horizon 
Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
TASMIN-SR           
10 years 
    
  
Usual care 
    
5,860  
  
5.1741  
  
  
Self-management 
     
5,237  
   
5.3506  -623 0.1765 
 
Dominant  
5 years 
    
  
Usual care 
    
3,109  
  
3.2475  
  
  
Self-management 
     
2,753  
   
3.3079  -356 0.0605 
 
Dominant  
3 years  
    
  
Usual care 
    
1,792  
  
2.1372  
  
  
Self-management 
     
1,626  
   
2.1564  -166 0.0192 
 
Dominant  
2 years 
    
  
Usual care 
    
1,173  
  
1.4889  
  
  
Self-management 
     
1,110  
   
1.4957  -63 0.0068 
 
Dominant  
1 year 
    
  
Usual care 
       
629  
  
0.7791  
  
  
Self-management 
        
652  
   
0.7797  23 0.0006 
      
35,391  
Model 1 
    
  
10 years 
    
  
Usual care 
    
5,729  
  
5.1310  
  
  
Self-management 
     
5,231  
   
5.3029  -498 0.1719 
 
Dominant  
5 years 
    
  
Usual care       
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Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
3,066  3.2371  
Self-management 
     
2,762  
   
3.2955  -304 0.0584 
 
Dominant  
3 years  
    
  
Usual care 
    
1,772  
  
2.1331  
  
  
Self-management 
     
1,630  
   
2.1516  -141 0.0185 
 
Dominant  
2 years 
    
  
Usual care 
    
1,162  
  
1.4871  
  
  
Self-management 
     
1,111  
   
1.4937  -51 0.0066 
 
Dominant  
1 year 
    
  
Usual care 
       
624  
  
0.7788  
  
  
Self-management 
        
650  
   
0.7795  25 0.0006 
      
40,799  
Model 2           
10 years 
    
  
Usual care 
    
5,738  
  
5.2904  
  
  
Self-management 
     
5,045  
   
5.4608  -692 0.1704 
 
Dominant  
5 years 
    
  
Usual care 
    
2,923  
  
3.3047  
  
  
Self-management 
     
2,565  
   
3.3580  -357 0.0533 
 
Dominant  
3 years  
    
  
Usual care 
    
1,644  
  
2.1624  
  
  
Self-management 
     
1,492  
   
2.1786  -152 0.0161 
 
Dominant  
2 years 
    
  
Usual care 
    
1,066  
  
1.5018  
  
  
Self-management         -52 0.0056  
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Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
1,014  1.5075  Dominant  
1 year 
    
  
Usual care 
       
566  
  
0.7830  
  
  
Self-management 
        
593  
   
0.7835  27 0.0005 
      
50,960  
Model 3 
    
  
10 years 
    
  
Usual care 
    
6,114  
  
4.4454  
  
  
Self-management 
     
5,641  
   
4.6811  -473 0.2357 
 
Dominant  
5 years 
    
  
Usual care 
    
3,481  
  
2.9515  
  
  
Self-management 
     
3,132  
   
3.0489  -348 0.0974 
 
Dominant  
3 years  
    
  
Usual care 
    
2,100  
  
2.0112  
  
  
Self-management 
     
1,903  
   
2.0448  -197 0.0336 
 
Dominant  
2 years 
    
  
Usual care 
    
1,402  
  
1.4255  
  
  
Self-management 
     
1,314  
   
1.4378  -89 0.0123 
 
Dominant  
1 year 
    
  
Usual care 
       
771  
  
0.7607  
  
  
Self-management 
        
785  
   
0.7619  14 0.0012 
      
11,701  
Model 4 
    
  
10 years 
    
  
Usual care 
       
6,880  
           
5.2107        
Self-management                     -905 0.1696  
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Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
5,975  5.3803  Dominant  
5 years 
    
  
Usual care 
       
3,470  
           
3.2711        
Self-management 
        
2,985  
            
3.3237  -485 0.0527 
 
Dominant  
3 years  
    
  
Usual care 
       
1,889  
           
2.1446        
Self-management 
        
1,685  
            
2.1611  -203 0.0165 
 
Dominant  
2 years 
    
  
Usual care 
       
1,194  
           
1.4907        
Self-management 
        
1,123  
            
1.4969  -71 0.0062 
 
Dominant  
1 year 
    
  
Usual care 
          
629  
           
0.7791        
Self-management 
           
652  
            
0.7797  23 0.0007 
                  
35,334  
 
 
The importance of model structure in the CEA 
 
 
Appendix 1 Table 7 Results of cost-effectiveness in Model 4 after increasing/decreasing the 
probability of having a second event   
Model structure Costs QALYs 
Incremental 
cost 
Incremental 
QALYs ICER 
Model 4            
Doubling the probability of having a second event  
Usual care 1,5528 6.0034 
   
Self-management 1,3925 6.3859 -1,603 0.3825 Dominant  
Halving the probability of having a second event  
Usual care 8,213 7.9957 
   
Self-management 7,351 8.2767 -862 0.2810 Dominant  
 
